3 / 22
Notes:
Volume 7, Issue 6 (Suppl)
J Gastrointest Dig Syst, an open access journal
ISSN: 2161-069X
Page 53
December 07-08, 2017 Madrid, Spain
&
13
th
International Conference on Clinical Gastroenterology & Hepatology
2
nd
International Conference on Digestive Diseases
CO-ORGANIZED EVENT
Dysregulation of KRAS signaling in pancreatic cancer is not associated with
KRAS
mutations and
outcome
Oliverius M
1
, Brynychova V
2
, Hughes D J
3
, Hlavac V
2
, Dvorak P
4
, Doherty J E
5
, Murray H A
5
and
Lemstrova R
6
1
Institute of Clinical and Experimental Medicine, Czech
2
National Institute of Public Health, Czech
3
Royal College of Surgeons in Ireland, Ireland
4
Charles University in Prague, Czech
5
Randox Laboratories Ltd, Crumlin, UK
6
Palacky University Olomouc and University Hospital Olomouc, Czech
Background:
Pancreatic ductal adenocarcinoma (PDAC) is known as cancer with very poor prognosis.
KRAS
oncogene is a
major driver of PDAC tumorigenesis but its role as prognostic or predictive factor is not clear. The aim of the present study
was to investigate the prognostic significance of
KRAS
downstream signaling pathway genes expression and association with
clinical characteristics in PDAC patients undergoing radical surgery.
Methods:
Tumors and adjacent non-neoplastic pancreatic tissues were examined in 45 patients with histologically verified
PDAC.
KRAS, BRAF
and
PIK3CA
gene mutation analysis was performed using the
KRAS/BRAF/PIK3CA
array. The transcript
profile of 52
KRAS
downstream signaling pathway genes was assessed using quantitative real-time polymerase chain reaction.
Results:
KRAS
mutation was detected in 80% of cases but the mutation status do not influence PDAC patient’s prognoses. The
genes of four signaling pathways downstream of
KRAS
including the PI3K/PDK1/AKT, RAL guanine nucleotide exchange
factor, RIN1/ABL, and RAF/MAPK pathways exhibited differential expression in PDAC compared to the adjacent normal
tissue. However, no significant differences in expression were evident between patients with KRAS mutated and wild type
tumors. Moreover, expression patterns of
KRAS
downstream signaling pathway do not associate with overall survival of
patients.
Conclusions:
KRAS
mutation is present in most cases of PDAC, but is not associated with changes in expression of
KRAS
downstream signaling pathways and clinical outcome.
Biography
Martin Oliverius is Deputy Head of Transplant Surgery Department and Director of small bowel transplantation program at Institute for Clinical and Experimental
Medicine, Pargue, Czech Republic.
martin.oliverius@medicon.czOliverius M et al., J Gastrointest Dig Syst 2017, 7:6(Suppl)
DOI: 10.4172/2161-069X-C1-059